We explored the use of their inhibitors, AR-C155858 (AR-C), a specific inhibitor of MCT1 and MCT2, and syrosingopine (SYRO), previously described as a dual MCT1 and MCT4 inhibitor but with a major affinity for MCT4, to reduce glycolysis and evaluate their effects on leukemic cell proliferation in vitro, in combination or not, with the more conventional chemotherapeutic agent used in myeloid leukemia, arabinosylcytosine (Ara-C) (8, 27, 28). The gene discussed is SLC16A3; the disease is myeloid leukemia.